GlobeNewsWire
13 Jul 2026, 06:30 UTC · 10w ago
Verdict
Headline takes no side. We score ALMR +0.80 across three claims — strongly bullish.
+0.80strongly bullish
More positive than 87% of ticker scores this week
What the story claims
3 claims · scored −1 bearish … +1 bullish
Alamar Biosciences will deploy its NULISAseq Neuro 220 panel to profile ~21,000 plasma samples from 10,000 participants in a national neurodegenerative disease initiative.
More positive than 93% of claims this week
The initiative includes the addition of a new eMTBR-Tau assay to the Neuro 220 panel, enabling blood-based representation of tau tangle burden.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 3 movers · tap to explore
More positive than 78% of claims this week
The resulting proteomic dataset will be made publicly accessible and linked to National Alzheimer’s Coordinating Center IDs for AI-driven discovery.
More positive than 52% of claims this week
Which stocks this story touches
More positive than 87% of ticker scores this week
The company announced a major national-scale partnership and initiative utilizing its proprietary NULISAseq Neuro 220 panel for Alzheimer's research.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Seeking Alpha
5h ago
+16.8%
Price agrees with the score
$33.20 vs $28.42 close before publication (Jul 10) · not market-adjusted
ALMR chart →
